Table 2.
Parameter estimates for the final pharmacokinetic model for indinavir and the results of bootstrap analysis
| Basic model | Final model | Bootstrap analysis | ||||
|---|---|---|---|---|---|---|
| Est | RSE (%) | Est | RSE (%) | Median | 95% PI | |
| CL/F (l h−1) | 49.3 | 6.19 | 46.8 | 5.75 | 46.6 | 41.5, 55.3 |
| θritonavir* | 0.362 | 7.27 | 0.354 | 6.07 | 0.357 | 0.314, 0.406 |
| θconcomitant NNRTI* | – | – | 1.41 | 4.78 | 1.41 | 1.27, 1.56 |
| V/F (l) | 77.2 | 5.03 | 82.3 | 4.70 | 81.8 | 74.4, 102. |
| ka (h−1) | 2.64 | 16.4 | 2.62 | 16.0 | 2.59 | 1.90, 3.93 |
| Lag-time (h)# | 0.483 | 2.40 | 0.485 | 1.79 | 0.485 | 0.431, 0.545 |
| IIV CL/F (%) | 34.8 | 24.1 | 24.2 | 44.5 | 24.4 | 11.2, 52.3 |
| IIV V/F (%) | 28.5 | 50.6 | 24.6 | 52.3 | 24.0 | 10.6, 77.7 |
| Correlation IIV CL/F-V/F | 0.729 | 44.4 | 0.629 | 84.8 | 0.757 | −1, 1- |
| IOV CL/F (%) | 21.2 | 40.6 | 20.9 | 37.0 | 20.5 | 11.5, 32.6 |
| IOV F (%) | 22.8 | 48.3 | 23.1 | 50.7 | 22.2 | 7.74, 56.5 |
| θfemale* | – | – | 1.48 | 16.7 | 1.46 | 0.882, 2.040 |
| Additive error (mg l−1) | 0.0491 | 17.0 | 0.0491 | 16.7 | 0.0492 | 0.0306, 0.0782 |
| Proportional error (%) | 35.0 | 6.06 | 35.3 | 6.18 | 34.8 | 25.0, 39.4 |
*
Relative change in pharmacokinetic parameter in the presence of the covariate, resulting in the following equations: CL/F = 46.8 × 0.354RTV × 1.41NNRTI, V/F = 77.2, F = 1 × 1.48SEX.
#
Only estimated when indinavir and ritonavir were combined. CL/F = clearance, V/F = volume of distribution, F = apparent bioavailability, ka = absorption rate constant, IIV = interindividual variability, IOV = interoccasion variability, Est = parameter estimate, RSE = relative standard error, PI = prediction interval.